亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Novel Compositions for Cancer Therapy (Proteasomes Inhibitors)

技術優勢: Simple synthesis Unique structure differentiate claimed compositions from other, known compositions of matter in vitro, in vivo and clinical studies Potent activity with low cytotoxicity Mechanism of action well understood through

技術應用: While most enabled for the treatment of diverse cancers e.g., myeloma, denocarcinoma, pancreatic cancer, B cell-related cancer and lymphomas, proteasomes inhibitors have also demonstrated utility for the treatment of diverse human diseases, including but not limited to retroviral infections such as human immunodeficiency virus-1 (HIV-1) infection, immune disorders, inflammation (epoxomicin), Stroke and neurodegenerative disease (via promotion of neurite outgrowth as described for lactacystin, omurolide, tyropeptin A, curcumin, capsaicin, and TMC-95A).

詳細技術說明: Within mammalian cells, proteasome inhibitors block the ability of proteasomes to degrade unneeded or damaged proteins. When administered, proteasome inhibitors have been shown to be effective for treatment of cancer, HIV infection and autoimmune diseases. UC inventors have isolated, characterized and synthesized a natural proteasome inhibitor, discovered from a tropical marine cyanobacteria. Proprietary compositions (parent and analogs), which have intriguing and unique structural features, are claimed for treatment of cancer and other diseases responsive to proteasome inhibition.

*Abstract: Medicinal chemistry programs based on natural product leads have generated a large number of synthetic analogues optimized for therapeutic use. The most successful example may be Carfilzomib, inspired in the natural product epoxomicin and currently in phase III clinical trials for multiple myeloma. The promise of proteasome inhibitors is validated by the first-in-class approved drug, Velcade as well as numerous proteasome inhibitors in clinical trials.

*IP Issue Date: Aug 9, 2016

*Principal Investigation: Name: Tara Byrum
Department:

Name: Hosana Debonsi
Department:

Name: Andrew Fenley
Department:

Name: William Gerwick
Department:

Name: Michael Gilson
Department:

Name: Andrew Kale
Department:

Name: Bradley Moore
Department:

Name: Alban Pereira
Department:

Name: Fred Valeriote
Department:

主要類別: 診斷/治療

細分類別: 人類免疫缺陷病毒

申請號碼: 9409944

其他

State Of Development

Assay-guided purification was used to identify and isolate the parent compounds, carmaphycins A and B work has demonstrated potent efficacy vs. human lung adenocarcinoma and colon cancer cells. The structures were elucidated by means of NMR and HRESIMS data and absolute and relative configurations were determined by total synthesis. A straightforward synthetic method has generated material sufficient to support in vivo assessment of efficacy of compositions.

Intellectual Property Info

Worldwide rights available; pending patents available under confidentiality.

Related Materials

Pereira, AR, et al., The Carmaphycins: New Proteasome Inhibitors Exhibiting an a, ß-Epoxyketone Warhead from a Marine Cyanobacterium
Inventor's Bio
Inventor information

Additional Technologies by these Inventors

Tech ID/UC Case

22376/2011-354-0

Related Cases

2011-354-0, 2010-351-0

國家/地區: 美國

欲了解更多信息，請點擊這裡